



10th July 2009

## **PRESS RELEASE**

### **UNIVERSITY COLLEGE LONDON HOSPITAL AND BLACKBURN WITH DARWEN PRIMARY CARE TRUST PURCHASE L-DEX™ DEVICES TO IMPROVE LYMPHOEDEMA ASSESSMENT**

NHS institutions continue to strive for excellence in patient care by utilising L-Dex U400 devices to assess the effectiveness of lymphoedema care.

“The Cancer and Supportive Care Team at University College London Hospital (UCLH) are using the L-Dex device to monitor lymphoedema and the effects of treatment and also feel it would be useful in a few cases to rule out any lymphoedema present in breast cancer survivors whose status is unclear,” said Consultant Nurse, Cancer & Supportive Care, Kay Eaton.

At Blackburn with Darwen Primary Care Trust (BWD PCT) Debbie Murphy, Advanced Practitioner for Tissue Viability & Vascular Services and her team are using the L-Dex U400 for research and in the clinic. Providing lymphoedema services to patients is extremely important and the L-Dex device allows us to effectively assess therapies. We are always looking at improving services to the community and the earlier we can assess lymphoedema the better we are able to manage the disorder.” Debbie stated.

A 2008 publication by Dr. Sandi Hayes et al (QUT) concluded that lymphoedema occurs in roughly one third of breast cancer patients post-treatment, much of which (40-60%) is being missed in its early stages by manual assessment methods<sup>1</sup>.

“ImpediMed’s L-Dex devices are used for both pre-emptive care through early assessment, and in follow up for efficacy of treatment in lymphoedema patients. Having such prestigious institutions as UCLH and BWD PCT adopt L-Dex for monitoring treatment efficacy in lymphoedema patients is also very important for the acceptance of L-Dex,” commented Greg Brown, CEO of ImpediMed.

Mr Brown added, “L-Dex provides lymphoedema carers with a standardised, objective metric. The hallmark of successful care is the ability to document the efficacy of any therapeutic intervention. L-Dex provides healthcare professionals with a standardised metric that aids in assessing the response of a patient to therapy. This helps the physician in their clinical assessment of the disorder and ultimately helps in decisions about treatment options for the patient.”

**ENDS**

## For further information contact:

**Greg Brown**

**ImpediMed CEO**

**+61-7-3860-3700**

1. Hayes S, Janda M, Cornish B, Battistutta D, Newman B. Lymphedema Secondary to Breast Cancer: How Choice of Measure Influences Diagnosis, Prevalence, and Identifiable Risk Factors. *Lymphology*. 41 2008 18-28

L-Dex™ is a trademark of ImpediMed Limited

L-Dex™ values that lie outside the normal range may indicate the early signs of lymphoedema and values that have changed +10 L-Dex units from baseline may also indicate early lymphoedema. The L-Dex scale is a tool to assist in the clinical assessment of lymphoedema by a medical provider. The L-Dex scale is not intended to diagnose or predict lymphoedema of an extremity.

### **About ImpediMed**

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed had the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary lymphoedema of the arm in female breast cancer patients. For more information, visit. [www.impedimed.com](http://www.impedimed.com).